Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 21, 2021 9:28am
227 Views
Post# 33247006

RE:RE:RE:RE:15$ US Target reiterated today as well

RE:RE:RE:RE:15$ US Target reiterated today as wellWith the $15 usd one yr target being reinforced, and favourable write up from Doug Mm ( RBC capital) ...They still predict PH3 announcement before end of this year.
that would mean a partnership & emediate SP doubling, at that announcement.
going into long weekend TSX is closed Monday, but NAS is open.
With Panc cancer follow up June 5 Th, and 2-3 other catalysts expected next 2-3 months....
My prediction we get through $4 CDN today.
Pre- partnership announcement this fall, in the $5-$6 range.
Post PH3 announcement Dec in the $10;CDN range.
ONC does not need to tap the ATM until early 2022, so the price can run on its own.
stay tuned.

<< Previous
Bullboard Posts
Next >>